Avenue Therapeutics, Inc. (ATXI)

US — Healthcare Sector
Peers: ADTX  MTVA  DRMA  UNCY  REVB  ARDS  PALI  ENSC 

Automate Your Wheel Strategy on ATXI

With Tiblio's Option Bot, you can configure your own wheel strategy including ATXI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATXI
  • Rev/Share 0.0
  • Book/Share 0.785
  • PB 0.3089
  • Debt/Equity 0.0
  • CurrentRatio 2.775
  • ROIC -4.228

 

  • MktCap 1162014.0
  • FreeCF/Share -2.3872
  • PFCF -0.1638
  • PE -0.0794
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -3.9933

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Avenue Therapeutics, Inc. (ATXI)

  • IPO Date 2017-06-27
  • Website https://www.avenuetx.com
  • Industry Biotechnology
  • CEO Alexandra MacLean
  • Employees 2
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.